Faron Pharmaceuticals Oy
LSE:FARN
Intrinsic Value
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of treatment for acute organ traumas, vascular damage, and cancer immunotherapy. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of FARN.
Faron Pharmaceuticals Oy's market capitalization is 82.5m GBX.
FARN stock price is 120 GBX.
FARN.
FARN. Open DCF Valuation
FARN. Open Relative Valuation
FARN.
FARN has negative Free Cash Flow for the last twelve months.
FARN has positive Net Debt. This means that the company has more debt (9m EUR) than cash and short-term investments (7m EUR).
FARN has negative Operating Income for the last twelve months.
FARN has negative Net Income for the last twelve months.
FARN's ROE (Return on Equity) has significantly decreased in the last 3 years from 14 181% to 232%.
FARN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 20 077% to 776%.
FARN's ROE (Return on Equity) for the past 12 months is very high and is equal to 232%.
FARN's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 776%.
FARN's short-term liabilties (15m EUR) exceed its short-term assets (9m EUR).
FARN's long-term liabilties (25m EUR) exceed its long-term assets (10m EUR).
FARN has very high three-year average ROE (Return on Equity): 1 874%. The company is very efficient at transforming stockholders' equity into net income.
FARN has very high three-year average ROIC (Return on Invested Capital): 3 412%. The company is very efficient at using invested capital to generate operating income.
FARN's D/E (Debt to Equity) is very low and is equal to -0.62.
FARN's Altman Z-Score is very low and is equal to -8.24.
FARN doesn't generate enough operating income (-29m EUR) to safely cover interest payments on its debt (1m EUR).
Fundamental Analysis
Faron Pharmaceuticals Oy
Balance Sheet Decomposition
Faron Pharmaceuticals Oy
| Current Assets | 8.9m |
| Cash & Short-Term Investments | 6.9m |
| Other Current Assets | 2m |
| Non-Current Assets | 1.4m |
| PP&E | 204k |
| Intangibles | 1.1m |
| Other Non-Current Assets | 60k |
| Current Liabilities | 15m |
| Accounts Payable | 9m |
| Other Current Liabilities | 6m |
| Non-Current Liabilities | 10.4m |
| Long-Term Debt | 9.5m |
| Other Non-Current Liabilities | 895k |
Earnings Waterfall
Faron Pharmaceuticals Oy
|
Revenue
|
0
EUR
|
|
Operating Expenses
|
-28.6m
EUR
|
|
Operating Income
|
-28.6m
EUR
|
|
Other Expenses
|
-2.4m
EUR
|
|
Net Income
|
-30.9m
EUR
|
Free Cash Flow Analysis
Faron Pharmaceuticals Oy
What is Free Cash Flow?
FARN Profitability Score
Profitability Due Diligence
Faron Pharmaceuticals Oy's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
Faron Pharmaceuticals Oy's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
FARN Solvency Score
Solvency Due Diligence
Faron Pharmaceuticals Oy's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
Faron Pharmaceuticals Oy's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FARN Price Targets Summary
Faron Pharmaceuticals Oy
Shareholder Return
FARN Price
Faron Pharmaceuticals Oy
| Average Annual Return | 95.33% |
| Standard Deviation of Annual Returns | 180.81% |
| Max Drawdown | -76% |
| Market Capitalization | 82.5m GBX |
| Shares Outstanding | 68 807 200 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Faron Pharmaceuticals Oy
Country
Industry
Market Cap
Dividend Yield
Description
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of treatment for acute organ traumas, vascular damage, and cancer immunotherapy. The company is headquartered in Turku, Lansi-Suomen and currently employs 37 full-time employees. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.
You don't have any saved screeners yet
